Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from F/HN-pseudotyped lentiviral vector efficiently transduces non-human primate airways with no evidence of relevant toxicity. Local targets link to admitted publications; unresolved targets remain external evidence.
Future therapies for cystic fibrosis
10.1038/s41467-023-36244-2 · 2023 · External reference
Cystic fibrosis gene therapy: looking back, looking forward
10.3390/genes9110538 · 2018 · External reference
Toward gene therapy for cystic fibrosis using a lentivirus pseudotyped with Sendai virus envelopes
10.1038/mt.2010.13 · 2010 · External reference
Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial
10.1016/s2213-2600(15)00245-3 · 2015 · External reference
Gene therapy for respiratory diseases: progress and a changing context
10.1089/hum.2020.142 · 2020 · External reference
Gene, RNA, and ASO-based therapeutic approaches in cystic fibrosis
10.1016/j.jcf.2022.12.016 · 2023 · External reference
Viral vector platforms within the gene therapy landscape
10.1038/s41392-021-00487-6 · 2021 · External reference
Progress in respiratory gene therapy
10.1089/hum.2022.172 · 2022 · External reference
rAAV-CFTRΔR rescues the cystic fibrosis phenotype in human intestinal organoids and cystic fibrosis mice
10.1164/rccm.201505-0914oc · 2015 · External reference
Efficient gene transfer to airway epithelium using recombinant Sendai virus
10.1038/79463 · 2000 · External reference
A defective nontransmissible recombinant Sendai virus mediates efficient gene transfer to airway epithelium in vivo
10.1038/sj.gt.3302334 · 2004 · External reference
Development of Sendai virus vectors and their potential applications in gene therapy and regenerative medicine
10.2174/156652312802762518 · 2012 · External reference
Lentiviral vectors and cystic fibrosis gene therapy
10.3390/v2020395 · 2010 · External reference
The GP120 molecule of HIV-1 and its interaction with T cells
10.2174/092986710790514499 · 2010 · External reference
Altering the tropism of lentiviral vectors through pseudotyping
10.2174/1566523054546224 · 2005 · External reference
Towards human translation of lentiviral airway gene delivery for cystic fibrosis: a one-month CFTR and reporter gene study in marmosets
10.1089/hum.2020.267 · 2021 · External reference
The effects of conditioning and lentiviral vector pseudotype on short- and long-term airway reporter gene expression in mice
10.1089/hum.2021.031 · 2021 · External reference
The dual-pseudotyped lentiviral vector with VSV-G and sendai virus HN enhances infection efficiency through the synergistic effect of the envelope proteins
10.3390/v16060827 · 2024 · External reference
Assessment of F/HN-pseudotyped lentivirus as a clinically relevant vector for lung gene therapy
10.1164/rccm.201206-1056oc · 2012 · External reference
Proliferative and nonproliferative lesions of the rat and mouse respiratory tract
10.1177/0192623309353423 · 2009 · External reference
Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis
10.1136/thoraxjnl-2016-208406 · 2017 · External reference
A developmental role of the cystic fibrosis transmembrane conductance regulator in cystic fibrosis lung disease pathogenesis
10.3389/fcell.2021.742891 · 2021 · External reference
Increased CFTR expression and function from an optimized lentiviral vector for cystic fibrosis gene therapy
10.1016/j.omtm.2021.02.020 · 2021 · External reference
Expression of gain-of-function CFTR in cystic fibrosis airway cells restores epithelial function better than wild-type or codon-optimized CFTR
10.1016/j.omtm.2023.08.006 · 2023 · External reference
Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA
10.1038/ng0293-151 · 1993 · External reference
Pharmacological and pre-clinical safety profile of rSIV.F/HN, a hybrid lentiviral vector for cystic fibrosis gene therapy
10.1183/13993003.01683-2023 · 2025 · External reference
A preclinical study in rhesus macaques for cystic fibrosis to assess gene transfer and transduction by AAV1 and AAV5 with a dual-luciferase reporter system
10.1089/humc.2017.067 · 2017 · External reference
Development, validation and use of ELISA for antibodies to human alpha-1 antitrypsin
10.1016/j.jim.2012.11.008 · 2013 · External reference
Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: safety and immunologic aspects
10.1006/mthe.2002.0673 · 2002 · External reference
The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches
10.1016/s0140-6736(23)01608-2 · 2023 · External reference
CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis
10.1016/s0140-6736(23)01609-4 · 2023 · External reference
Gene therapy for cystic fibrosis: challenges and prospects
10.3389/fphar.2022.1015926 · 2022 · External reference
Lentiviral gene therapy for cystic fibrosis: a promising approach and first-in-human trial
10.1164/rccm.202402-0389ci · 2024 · External reference
Contribution of Nonhuman Primate Models to Advances in Human Health
2023 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
2011 · External reference
Lung-targeting lentiviral vector for passive immunisation against influenza
10.1136/thoraxjnl-2020-214656 · 2020 · External reference
Symposium Summary: “Breathe In, Breathe Out, Its Easy: What You Need to Know About Developing Inhaled Drugs”
10.1177/1091581815624080 · 2016 · External reference
